Myeloma is staged based on the Revised International Staging System (R-ISS), which considers factors such as levels of beta-2 microglobulin, albumin, lactate dehydrogenase (LDH), and cytogenetic abnormalities. The stages are: - Stage I: Early disease with a lower amount of myeloma cells. - Stage II: Intermediate disease. - Stage III: Advanced disease with a higher number of myeloma cells and more aggressive features.
